Page of

Share this page

Share this page

Share this page

Share this page

Prolia and XGEVA - Amgen

Prix Galien USA Award Laureates Book

Leave a 'Tweet'.

Add your tribute to this Research Team here in words, pictures and video clips.

Dear Colleague, As a way of celebrating and sharing and sharing the Galien Awards, a page has been created within the $bookTitle$. Here we can all share our memories – through stories, thoughts, messages, photographs and videos. If you would like to visit the page please go to $findPersonLink Thank you,
Winning Products Index 2011 Next

Winning Product Details by: Galien Foundation

Date added: 18 Mar 2014

2011 - Best Biotechnology Product: Prolia and XGEVA® - Amgen

Amgen’s discovery of a critical physiologic pathway that regulates bone metabolism led to a new approach for the treatment of bone loss and destruction. As a first-in-class RANKL inhibitor, denosumab constitutes a bench-tobedside therapeutic concept for a variety of bone diseases. Extensive and thorough clinical development programs supported approval of denosumab for the treatment of postmenopausal osteoporosis and the prevention of skeletal-related events across a variety of advanced cancers metastatic to bone.

Next Previous